Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) lost significant market capitalization on May 16, 2026, when the Company disclosed that its Phase 3 melanoma trial of fianlimab combined with Libtayo failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here.

GlobeNewsWire • 20 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • 10 hours ago

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or cardiac involvement demonstrated improvement in organ function, despite short follow-up First results from the Phase 1/2 LINKER-AL2 trial to be detailed in an ASCO oral presentation; the Phase 2 portion of the trial with registrational intent is ongoing TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2 trial evaluating Lynozyfic® (linvoseltamab) in adults with second-line-plus systemic amyloid light chain (AL) amyloidosis, which will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting on Friday, May 29 at 2:45 p.m.

GlobeNewsWire • 12 hours ago

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. During the Q1 2026 e.

Business Wire • May 20, 2026

REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations

Regeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in. NEW YORK, May 19, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw the stock decline more than 10% when the market opened on May 18, 2026 after investors digested the weekend news that Regeneron's Phase 3 melanoma trial of Fianlimab + Libtayo failed to meet its primary endpoint versus Merck's Keytruda (pembrolizumab).

PRNewsWire • May 19, 2026

Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B

REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.

Zacks Investment Research • May 19, 2026

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

Zacks Investment Research • May 19, 2026

Regeneron drops after skin cancer treatment misses late-stage trial goal

Shares of Regeneron fell 11.8% premarket on Monday after the company's ​experimental treatment missed the main goal in ‌a late-stage trial in patients with advanced melanoma, a type of skin cancer.

Reuters • May 18, 2026

The Surprising Reason Regeneron Pharmaceuticals Just Dropped 12%

Regeneron Pharmaceuticals stock crashed Monday after its experimental melanoma treatment failed in Phase 3 testing.

Investors Business Daily • May 18, 2026

Regeneron stock drops double digits on oncology trial failure

Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal late-stage clinical trial. The sharp selloff followed Regeneron's announcement that its high-dose fianlimab and cemiplimab combination failed to significantly outperform Merck's Keytruda in a Phase 3 study involving patients with previously untreated metastatic melanoma.

Invezz • May 18, 2026